Ruxolitinib Treatment Induces a Transition of Classical to Non-Classical Monocytes in Patients with Myelofibrosis

We examined the clinical usefulness of 3 parameters of routine laboratory tests [platelet-large cell ratio (P-LCR), lactate dehydrogenase (LDH) and C-reactive protein (CRP)] in 84 patients with thrombocytosis-related diseases (reactive thrombocytosis, chronic myeloid leukemia, essential thrombocythemia and polycythemia vera). These thrombocytosis-related diseases were characterized using the 3 parameters P-LCR, LDH and CRP as follows: high P-LCR and high LDH in chronic myeloid leukemia; high CRP in reactive thrombocytosis; slightly high P-LCR and high LDH in essential thrombocythemia and polycythemia vera. For essential thrombocythemia and polycythemia vera, levels of P-LCR and CRP were nearly identical, but the LDH level in essential thrombocythemia was significantly higher than in polycythemia vera. These characteristics of P-LCR, LDH and CRP may be useful for simple and very rough differentiation of the thrombocytosis-related disease mentioned above.

Thrombocytosis

Myeloproliferative Disorders

Polycythemia rubra vera

10.1159/000105167

Cite

Citations (11)

6-Thioguanine treatment of uncontrolled thrombocytosis in polycythemia vera and essential thrombocythemia.

PubMed (1984)

C Delfini Antonio Porcellini T Izzi D Baronciani

Thrombocytosis

Plateletpheresis

Source

Cite

Citations (0)

Thrombocytosis in young people: Evaluation of 57 cases diagnosed before the age of 40

Blut Zeitschrift für die gesamte Blutforschung (1990)

M. L. Randi F. Fabris Antonio Girolami

Thrombocytosis

10.1007/bf01728790

Cite

Citations (32)

Are polycythemia vera, essential thrombocytosis, and primary myelofibrosis 1, 2, or 3 diseases?

Leukemia (2021)

Jerry L. Spivak

Thrombocytosis

Ruxolitinib

Polycythemia rubra vera

Hematology

Myeloproliferative Disorders

10.1038/s41375-021-01254-w

Cite

Citations (4)

Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis

Internal Medicine (2017)

Megumi Koshiishi Yuki Sueki Ichiro Kawashima Kei Nakajima Toru Mitsumori

The development of tumor lysis syndrome (TLS) in association with treatment for myeloproliferative neoplasms (MPNs) is relatively rare. We herein present the case of a post-polycythemia vera (PV) myelofibrosis patient with massive splenomegaly who developed laboratory TLS after treatment with ruxolitinib, a potent JAK1/JAK2 inhibitor. She also exhibited a rapid reduction of spleen volume. Our present case suggests the potential risk of TLS development after ruxolitinib treatment, particularly in patients with massive splenomegaly.

Ruxolitinib

Myeloproliferative neoplasm

10.2169/internalmedicine.8706-16

Cite

Citations (5)

Ruxolitinib in Myelofibrosis and Polycythemia Vera

Journal of the Advanced Practitioner in Oncology (2016)

Leah Wolfe

Ruxolitinib

10.6004/jadpro.2016.7.4.6

Cite

Citations (10)